Cargando…
Low frequency of mismatch repair deficiency in gallbladder cancer
BACKGROUND: DNA mismatch repair (MMR) deficiency is a major pathway of genomic instability in cancer. It leads to the accumulation of numerous mutations predominantly at microsatellite sequences, a phenotype known as microsatellite instability (MSI). MSI tumors have a distinct clinical behavior and...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506936/ https://www.ncbi.nlm.nih.gov/pubmed/31068195 http://dx.doi.org/10.1186/s13000-019-0813-5 |
_version_ | 1783416937661857792 |
---|---|
author | Goeppert, Benjamin Roessler, Stephanie Renner, Marcus Loeffler, Moritz Singer, Stephan Rausch, Melina Albrecht, Thomas Mehrabi, Arianeb Vogel, Monika Nadja Pathil, Anita Czink, Elena Köhler, Bruno Springfeld, Christoph Rupp, Christian Weiss, Karl Heinz Schirmacher, Peter von Knebel Doeberitz, Magnus Kloor, Matthias |
author_facet | Goeppert, Benjamin Roessler, Stephanie Renner, Marcus Loeffler, Moritz Singer, Stephan Rausch, Melina Albrecht, Thomas Mehrabi, Arianeb Vogel, Monika Nadja Pathil, Anita Czink, Elena Köhler, Bruno Springfeld, Christoph Rupp, Christian Weiss, Karl Heinz Schirmacher, Peter von Knebel Doeberitz, Magnus Kloor, Matthias |
author_sort | Goeppert, Benjamin |
collection | PubMed |
description | BACKGROUND: DNA mismatch repair (MMR) deficiency is a major pathway of genomic instability in cancer. It leads to the accumulation of numerous mutations predominantly at microsatellite sequences, a phenotype known as microsatellite instability (MSI). MSI tumors have a distinct clinical behavior and commonly respond well to immune checkpoint blockade, irrespective of their origin. Data about the prevalence of MSI among gallbladder cancer (GBC) have been conflicting. We here analyzed a well-characterized cohort of 69 Western-world GBCs. METHODS: We analyzed the mononucleotide MSI marker panel consisting of BAT25, BAT26, and CAT25 to determine the prevalence of MMR deficiency-induced MSI. RESULTS: MSI was detected in 1/69 (1.4%) of analyzed GBCs. The detected MSI GBC had a classical histomorphology, i.e. of acinar/tubular/glandular pancreatobiliary phenotype, and showed nuclear expression of all four MMR proteins MLH1, MSH2, MSH6, and PMS2. The MSI GBC patient showed a prolonged overall survival, despite having a high tumor stage at diagnosis. The patient had no known background or family history indicative of Lynch syndrome. CONCLUSIONS: Even though the overall number of MSI tumors is low in GBC, the potentially therapeutic benefit of checkpoint blockade in the respective patients may justify MSI analysis of GBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13000-019-0813-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6506936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65069362019-05-13 Low frequency of mismatch repair deficiency in gallbladder cancer Goeppert, Benjamin Roessler, Stephanie Renner, Marcus Loeffler, Moritz Singer, Stephan Rausch, Melina Albrecht, Thomas Mehrabi, Arianeb Vogel, Monika Nadja Pathil, Anita Czink, Elena Köhler, Bruno Springfeld, Christoph Rupp, Christian Weiss, Karl Heinz Schirmacher, Peter von Knebel Doeberitz, Magnus Kloor, Matthias Diagn Pathol Research BACKGROUND: DNA mismatch repair (MMR) deficiency is a major pathway of genomic instability in cancer. It leads to the accumulation of numerous mutations predominantly at microsatellite sequences, a phenotype known as microsatellite instability (MSI). MSI tumors have a distinct clinical behavior and commonly respond well to immune checkpoint blockade, irrespective of their origin. Data about the prevalence of MSI among gallbladder cancer (GBC) have been conflicting. We here analyzed a well-characterized cohort of 69 Western-world GBCs. METHODS: We analyzed the mononucleotide MSI marker panel consisting of BAT25, BAT26, and CAT25 to determine the prevalence of MMR deficiency-induced MSI. RESULTS: MSI was detected in 1/69 (1.4%) of analyzed GBCs. The detected MSI GBC had a classical histomorphology, i.e. of acinar/tubular/glandular pancreatobiliary phenotype, and showed nuclear expression of all four MMR proteins MLH1, MSH2, MSH6, and PMS2. The MSI GBC patient showed a prolonged overall survival, despite having a high tumor stage at diagnosis. The patient had no known background or family history indicative of Lynch syndrome. CONCLUSIONS: Even though the overall number of MSI tumors is low in GBC, the potentially therapeutic benefit of checkpoint blockade in the respective patients may justify MSI analysis of GBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13000-019-0813-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-08 /pmc/articles/PMC6506936/ /pubmed/31068195 http://dx.doi.org/10.1186/s13000-019-0813-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Goeppert, Benjamin Roessler, Stephanie Renner, Marcus Loeffler, Moritz Singer, Stephan Rausch, Melina Albrecht, Thomas Mehrabi, Arianeb Vogel, Monika Nadja Pathil, Anita Czink, Elena Köhler, Bruno Springfeld, Christoph Rupp, Christian Weiss, Karl Heinz Schirmacher, Peter von Knebel Doeberitz, Magnus Kloor, Matthias Low frequency of mismatch repair deficiency in gallbladder cancer |
title | Low frequency of mismatch repair deficiency in gallbladder cancer |
title_full | Low frequency of mismatch repair deficiency in gallbladder cancer |
title_fullStr | Low frequency of mismatch repair deficiency in gallbladder cancer |
title_full_unstemmed | Low frequency of mismatch repair deficiency in gallbladder cancer |
title_short | Low frequency of mismatch repair deficiency in gallbladder cancer |
title_sort | low frequency of mismatch repair deficiency in gallbladder cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506936/ https://www.ncbi.nlm.nih.gov/pubmed/31068195 http://dx.doi.org/10.1186/s13000-019-0813-5 |
work_keys_str_mv | AT goeppertbenjamin lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT roesslerstephanie lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT rennermarcus lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT loefflermoritz lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT singerstephan lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT rauschmelina lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT albrechtthomas lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT mehrabiarianeb lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT vogelmonikanadja lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT pathilanita lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT czinkelena lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT kohlerbruno lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT springfeldchristoph lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT ruppchristian lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT weisskarlheinz lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT schirmacherpeter lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT vonknebeldoeberitzmagnus lowfrequencyofmismatchrepairdeficiencyingallbladdercancer AT kloormatthias lowfrequencyofmismatchrepairdeficiencyingallbladdercancer |